Selected research
Industry Growth & Trends
Global Acute Agitation and Aggression Therapeutics Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Acute Agitation and Aggression Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Acute Agitation and Aggression Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Acute Agitation and Aggression Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Acute Agitation and Aggression Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Acute Agitation and Aggression Therapeutics market include Johnson & Johnson, Eli Lilly and Company, Pfizer, GlaxoSmithKline, Otsuka Holdings, Ono Pharmaceutical, H. Lundbeck A/S and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Acute Agitation and Aggression Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Acute Agitation and Aggression Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Acute Agitation and Aggression Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Acute Agitation and Aggression Therapeutics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Acute Agitation and Aggression Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Acute Agitation and Aggression Therapeutics Market by Company
Johnson & Johnson
Eli Lilly and Company
Pfizer
GlaxoSmithKline
Otsuka Holdings
Ono Pharmaceutical
H. Lundbeck A/S
Bristol-Myers Squibb
Acute Agitation and Aggression Therapeutics Segment by Type
Oral
Intramuscular Injection
Others
Acute Agitation and Aggression Therapeutics Segment by Application
Oral
Intramuscular Injection
Others
Acute Agitation and Aggression Therapeutics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Agitation and Aggression Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Acute Agitation and Aggression Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Agitation and Aggression Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Acute Agitation and Aggression Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Intramuscular Injection
- Others
Applications
- Oral
- Intramuscular Injection
- Others
Companies covered
- Johnson & Johnson
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Otsuka Holdings
- Ono Pharmaceutical
- H. Lundbeck A/S
- Bristol-Myers Squibb
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Acute Agitation and Aggression Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Acute Agitation and Aggression Therapeutics Market Size by Region (2021-2032)
- 1.4.1 Global Acute Agitation and Aggression Therapeutics Market Size by Region (2021-2026)
- 1.4.2 Global Acute Agitation and Aggression Therapeutics Market Size by Region (2027-2032)
- 1.5 Key Regions Acute Agitation and Aggression Therapeutics Market Size (2021-2032)
- 1.5.1 North America Acute Agitation and Aggression Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Acute Agitation and Aggression Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Acute Agitation and Aggression Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.4 South America Acute Agitation and Aggression Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Acute Agitation and Aggression Therapeutics Market Size Growth Rate (2021-2032)
2 Acute Agitation and Aggression Therapeutics Market by Type
- 2.1 Type Introduction
- 2.1.1 Oral
- 2.1.2 Intramuscular Injection
- 2.1.3 Others
- 2.2 Global Acute Agitation and Aggression Therapeutics Market Size by Type
- 2.2.1 Global Acute Agitation and Aggression Therapeutics Market Size Overview by Type (2021-2032)
- 2.2.2 Global Acute Agitation and Aggression Therapeutics Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Acute Agitation and Aggression Therapeutics Market Size Forecasted by Type (2027-2032)
- 2.3 Global Acute Agitation and Aggression Therapeutics Market Size by Regions
- 2.3.1 North America Acute Agitation and Aggression Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Acute Agitation and Aggression Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Acute Agitation and Aggression Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Acute Agitation and Aggression Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Acute Agitation and Aggression Therapeutics Market Size Breakdown by Type (2021-2026)
3 Acute Agitation and Aggression Therapeutics Market by Application
- 3.1 Type Introduction
- 3.1.1 Oral
- 3.1.2 Intramuscular Injection
- 3.1.3 Others
- 3.2 Global Acute Agitation and Aggression Therapeutics Market Size by Application
- 3.2.1 Global Acute Agitation and Aggression Therapeutics Market Size Overview by Application (2021-2032)
- 3.2.2 Global Acute Agitation and Aggression Therapeutics Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Acute Agitation and Aggression Therapeutics Market Size Forecasted by Application (2027-2032)
- 3.3 Global Acute Agitation and Aggression Therapeutics Market Size by Regions
- 3.3.1 North America Acute Agitation and Aggression Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Acute Agitation and Aggression Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Acute Agitation and Aggression Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Acute Agitation and Aggression Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Acute Agitation and Aggression Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Acute Agitation and Aggression Therapeutics Industry Trends
- 4.2 Acute Agitation and Aggression Therapeutics Industry Drivers
- 4.3 Acute Agitation and Aggression Therapeutics Industry Opportunities and Challenges
- 4.4 Acute Agitation and Aggression Therapeutics Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Acute Agitation and Aggression Therapeutics Revenue (2021-2026)
- 5.2 Global Acute Agitation and Aggression Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Acute Agitation and Aggression Therapeutics Key Company Headquarters & Area Served
- 5.4 Global Acute Agitation and Aggression Therapeutics Company, Product Type & Application
- 5.5 Global Acute Agitation and Aggression Therapeutics Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Acute Agitation and Aggression Therapeutics Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Acute Agitation and Aggression Therapeutics Players Market Share by Revenue in 2025
- 5.6.3 2025 Acute Agitation and Aggression Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Johnson & Johnson
- 6.1.1 Johnson & Johnson Company Information
- 6.1.2 Johnson & Johnson Business Overview
- 6.1.3 Johnson & Johnson Acute Agitation and Aggression Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Johnson & Johnson Acute Agitation and Aggression Therapeutics Product Portfolio
- 6.1.5 Johnson & Johnson Recent Developments
- 6.2 Eli Lilly and Company
- 6.2.1 Eli Lilly and Company Company Information
- 6.2.2 Eli Lilly and Company Business Overview
- 6.2.3 Eli Lilly and Company Acute Agitation and Aggression Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Eli Lilly and Company Acute Agitation and Aggression Therapeutics Product Portfolio
- 6.2.5 Eli Lilly and Company Recent Developments
- 6.3 Pfizer
- 6.3.1 Pfizer Company Information
- 6.3.2 Pfizer Business Overview
- 6.3.3 Pfizer Acute Agitation and Aggression Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Pfizer Acute Agitation and Aggression Therapeutics Product Portfolio
- 6.3.5 Pfizer Recent Developments
- 6.4 GlaxoSmithKline
- 6.4.1 GlaxoSmithKline Company Information
- 6.4.2 GlaxoSmithKline Business Overview
- 6.4.3 GlaxoSmithKline Acute Agitation and Aggression Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 GlaxoSmithKline Acute Agitation and Aggression Therapeutics Product Portfolio
- 6.4.5 GlaxoSmithKline Recent Developments
- 6.5 Otsuka Holdings
- 6.5.1 Otsuka Holdings Company Information
- 6.5.2 Otsuka Holdings Business Overview
- 6.5.3 Otsuka Holdings Acute Agitation and Aggression Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Otsuka Holdings Acute Agitation and Aggression Therapeutics Product Portfolio
- 6.5.5 Otsuka Holdings Recent Developments
- 6.6 Ono Pharmaceutical
- 6.6.1 Ono Pharmaceutical Company Information
- 6.6.2 Ono Pharmaceutical Business Overview
- 6.6.3 Ono Pharmaceutical Acute Agitation and Aggression Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Ono Pharmaceutical Acute Agitation and Aggression Therapeutics Product Portfolio
- 6.6.5 Ono Pharmaceutical Recent Developments
- 6.7 H. Lundbeck A/S
- 6.7.1 H. Lundbeck A/S Company Information
- 6.7.2 H. Lundbeck A/S Business Overview
- 6.7.3 H. Lundbeck A/S Acute Agitation and Aggression Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 H. Lundbeck A/S Acute Agitation and Aggression Therapeutics Product Portfolio
- 6.7.5 H. Lundbeck A/S Recent Developments
- 6.8 Bristol-Myers Squibb
- 6.8.1 Bristol-Myers Squibb Company Information
- 6.8.2 Bristol-Myers Squibb Business Overview
- 6.8.3 Bristol-Myers Squibb Acute Agitation and Aggression Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Bristol-Myers Squibb Acute Agitation and Aggression Therapeutics Product Portfolio
- 6.8.5 Bristol-Myers Squibb Recent Developments
7 North America
- 7.1 North America Acute Agitation and Aggression Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Acute Agitation and Aggression Therapeutics Market Size by Country (2021-2026)
- 7.3 North America Acute Agitation and Aggression Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Acute Agitation and Aggression Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Acute Agitation and Aggression Therapeutics Market Size by Country (2021-2026)
- 8.3 Europe Acute Agitation and Aggression Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Acute Agitation and Aggression Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Acute Agitation and Aggression Therapeutics Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Acute Agitation and Aggression Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Acute Agitation and Aggression Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Acute Agitation and Aggression Therapeutics Market Size by Country (2021-2026)
- 10.3 South America Acute Agitation and Aggression Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Acute Agitation and Aggression Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Acute Agitation and Aggression Therapeutics Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Acute Agitation and Aggression Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst